Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Recent evidence-based coverage of peptide science, regulation, clinical research, and misinformation.
The FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A Bulks List. Here is a detailed breakdown of stakeholder reactions and the next steps in the regulatory process.
Day 2 of the FDA PCAC meeting produced mixed results: Epitalon passed 7-4, Semax passed 8-5, and Emideltide was the only peptide voted down across both days, failing 6-7. Here is the full breakdown.
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on Day 1 to recommend BPC-157, KPV, and TB-500 for the 503A Bulks List, with MOTS-c passing 7-5. Here is a full breakdown of what happened, what was voted on, and what it means.
On July 23–24, the FDA's Pharmacy Compounding Advisory Committee will review seven popular peptides. We break down the agenda, the end of the Category 1 vs. Category 2 era, and the realistic odds for each substance.
KPV (Lysine-Proline-Valine) is a potent anti-inflammatory tripeptide derived from alpha-MSH. As the July 2026 FDA PCAC review approaches, we explore how this 'microscopic miracle' is transforming the treatment of gut and skin inflammation.
An evidence-based review of Thymosin Alpha-1 (TA-1, thymalfasin): biochemistry, mechanisms, clinical trial evidence in viral disease and oncology, safety, and the U.S. 503A Category 2 reclassification.
Semax and Selank are two of the most popular central nervous system peptides in the biohacking community. Discover what the latest 2026 clinical science reveals about their mechanisms, benefits, and differences.
NMN or NR? Discover the landmark 2026 human clinical trial results comparing these ultimate NAD+ precursors for mitochondrial health and cellular longevity.
Losing weight on semaglutide or tirzepatide? Discover how the muscle-preserving peptide stack using sermorelin and amino acids protects lean mass while burning fat.
The FDA is convening an Advisory Committee to review compounded peptides. Discover what this means for Epithalon, BPC-157, and the future of longevity medicine.
What is MOTS-c? Discover the science behind the MOTS-c exercise mimetic peptide, its role in insulin sensitivity, mitochondrial health, and 2026 research updates.
Discover the scientific GHK-Cu copper peptide benefits for skin barrier repair and hair growth. Learn the biological mechanisms and clinical evidence.
Discover the latest retatrutide weight loss results from the Phase 3 TRIUMPH-1 trial. Learn how this triple agonist peptide achieves bariatric-level results.
The Lancet just published the Phase IIb results for elecoglipron, AstraZeneca's once-daily oral GLP-1 receptor agonist. Alex Keane analyzes the VISTA and SOLSTICE clinical data, the science of oral small molecules, and what this means for the future of obesity and diabetes care.
Injectable peptide stacks are surging on social media. Alex Keane explains how to separate GLP-1 evidence from the BPC-157, TB-500, and wellness-peptide evidence gap.
Retatrutide is surging in search and social conversation. Alex Keane explains the triple-agonist science, clinical data, and online peptide safety risks behind today’s trend.
Retatrutide is driving a new wave of peptide searches after Phase 3 weight-loss data. Alex Keane explains the triple-agonist science, safety signals, and why online peptide products deserve caution.
Retatrutide and BPC-157 are driving today’s peptide safety debate. Alex Keane explains why GLP-1 science, recovery peptides, and evidence gaps are colliding in 2026.
The 2026 FDA peptide reclassification is driving a significant shift in the regulatory landscape. Alex Keane explores how this impacts peptides like BPC-157 and the importance of regulation in GLP-1 success.
The 2026 FDA peptide reclassification is driving a significant shift in the regulatory landscape. Alex Keane explores how this impacts peptides like BPC-157 and the importance of regulation in GLP-1 success.
From muscle growth to weight loss, peptides offer promise and peril. Learn to distinguish between unregulated hype and FDA-approved science to make informed health decisions.
In the ever-evolving landscape of health and longevity, a new frontier is emerging: optimizing our cellular powerhouses—the mitochondria. While many peptides focus on hormonal regulation or tissue repair, a synergistic duo, SS-31 (Elamipretide) and MOTS-c, is rapidly gaining traction for its profound impact on cellular energy and metabolic health. Dubbed the "Mitochondrial Hardware/Software Stack" by biohacking communities, these peptides are not just trending on social media; they represent a sophisticated approach to enhancing vitality from the inside out.
No articles match that search.